Mirum Pharmaceuticals, Inc.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | May 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $176.2M | — | $159.9M | — | — | — | $133.0M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $81.5M | — | $96.3M | — | — | — | $61.9M |
| Operating Income | — | $-42.5M | — | $-789.5M | — | — | — | $2.6M |
| Operating Margin | — | -24.1% | — | -493.8% | — | — | — | 2.0% |
| Interest Expense | — | $2.6M | — | — | — | — | — | — |
| Pretax Income | — | $-65.5M | — | $-789.7M | — | — | — | $2.6M |
| Income Tax Expense | — | $1.7M | — | $475.0K | — | — | — | $-262.0K |
| Net Income | — | $-67.2M | — | $-790.2M | — | — | — | $2.9M |
| Net Margin | — | -38.1% | — | -494.2% | — | — | — | 2.2% |
| EPS (Basic) | — | $-1.06 | — | $-13.43 | — | — | — | $0.06 |
| EPS (Diluted) | — | $-1.06 | — | $-13.43 | — | — | — | $0.05 |
| Shares Outstanding (Basic) | 64.9M | 63.4M | 61.0M | 58.9M | 60.3M | 51.9M | 51.4M | 50.6M |
| Shares Outstanding (Diluted) | 64.9M | 63.4M | 61.0M | 58.9M | 60.3M | 51.9M | 51.4M | 57.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |